Sanofi and Regeneron's Dupixent shows more encouraging results


PARIS, April 3 (Reuters) - Healthcare companies Sanofi SASY.PA and Regeneron REGN.O announced on Friday more encouraging results for their Dupixent product used to treat severe atopic dermatitis, often commonly known as eczema.

The companies said that Dupixent Phase 3 data showed a significant improvement in severe atopic dermatitis for children aged 6 to 11 years.

Dupixent is an important driver of growth for both Sanofi and Regeneron, given the competition on Regeneron’s flagship eye drug Eylea and pressures on Sanofi’s diabetes business.

(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez)

((; +33 1 49 49 53 84;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.